Transplant Medicine
Researchers' data advance transplant medicine research
Published in Hepatitis Weekly, May 30th, 2005
Study 1: Combined therapy stems hepatitis B recurrence in liver transplant patients.
"Recurrence of hepatitis B impairs the outcome of liver transplantation (OLT). In serum hepatitis B virus (HBV)-DNA-positive recipients, prophylaxis using lamivudine and immunoglobulins (HBIg) reduces the risk of recurrence, but it is undefined whether this regimen also protects candidates with YMDD mutants. Seventeen OLT viremic candidates received preemptive lamivudine followed by post-OLT prophylaxis with lamivudine and HBIg," scientists in Italy report.
"Both...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-05-30)
More Articles from Hepatitis Weekly
- Antiviral Therapy
Chronic hepatitis C responds well to interferon alfacon-1 combination therapy - Diagnostics
Reverse micelles detect hepatitis B virus polymerase gene point mutations - Gastroenterology
Antiviral therapy for chronic hepatitis C may reveal latent Crohn disease - Hepatitis C Therapy
Early response to therapy improves prospects for chronic hepatitis C patients - Virology
Combination therapy helps patients with hepatitis B and C virus coinfection - Acute Liver Failure
HLA homozygosity confers susceptibility to non-A non-B hepatitis - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
